Revolution Medicines’ oral RAS inhibitor daraxonrasib (Rasonque) received FDA approval for metastatic pancreatic ductal adenocarcinoma after at least one prior systemic therapy, marking the first authorization of a RAS(ON) multi-selective targeted approach for this patient population. In the pivotal RASolute 302 Phase III trial (NCT06625320), daraxonrasib showed a median overall survival of 13.2 months versus 6.7 months with investigator’s choice chemotherapy in the intent-to-treat population, according to the StockWatch reporting. The FDA granted Priority Review and earlier Breakthrough Therapy and Orphan Drug designations, including acceptance into the Commissioner’s National Priority Voucher pilot. Even with the landmark decision, the market reaction described in the same report was muted at first, with investors split on near-term pricing and long-term sales potential—an issue that will likely shape uptake and competitive dynamics as RAS-targeted pancreatic therapy expands.